<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10-KSB

[X]      ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
         OF 1934

                   For the fiscal year ended    December 31, 2000
                                             -------------------------

[ ]      TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
         ACT OF 1934

          For the transition period from _____________ to _____________

                       Commission file number    000-27339
                                              -------------------------


                                 BEPARIKO BIOCOM
                -----------------------------------------------
                 (Name of small business issuer in its charter)


             NEVADA                                     88-0426887
------------------------------------       ------------------------------------
  (State or other jurisdiction of          (I.R.S. Employer Identification No.)
   incorporation or organization)

      150 West 46th Street
           5th Floor
       New York, New York                                 10034
------------------------------------       ------------------------------------
     (Address of principal                              (Zip Code)
       executive offices)

Issuer's telephone number:                (917) 450-8997
                           ---------------------------------------------

Securities registered under Section 12(b) of the Exchange Act:

        Title of each class           Name of each exchange on which registered

              None                                  Not Applicable
------------------------------------  ------------------------------------------

Securities registered under Section 12(g) of the Exchange Act:

                     Common Stock $0.001 par value per share
--------------------------------------------------------------------------------
                                (Title of class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [X]

State issuer's revenues for its most recent fiscal year:       $0.00

State the aggregate market value of the voting and non-voting common equity held
by non-affiliates based on the last sale price for the Registrant's common
stock: As at March 23, 2001, the aggregate market value of the Company's Common
Stock (based upon the last reported sale price on the National Association of
Securities Dealers OTC Bulletin Board), excluding outstanding shares
beneficially owned by affiliates, was approximately $29,457,000, being $5.13 per
share.

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date. As at March 23, 2001, there were
5,750,000 shares of Common stock issued and outstanding.

                       DOCUMENTS INCORPORATED BY REFERENCE

None

Transitional Small Business Disclosure Format (Check one): Yes      ; No  X
                                                               -----    -----




                                      -ii-
<PAGE>


                                TABLE OF CONTENTS
                                -----------------

                                     PART I

   ITEM 1 DESCRIPTION OF BUSINESS..............................................4
   ITEM 2 DESCRIPTION OF PROPERTY..............................................5
   ITEM 3 LEGAL PROCEEDINGS....................................................5
   ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS..................5

                                     PART II

   ITEM 5 MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.............5
   ITEM 6 MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION............6
   ITEM 7 FINANCIAL STATEMENTS................................................10
   ITEM 8 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
   FINANCIAL DISCLOSURE.......................................................10

                                    PART III

   ITEM 9 DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS;
   COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT..........................11
   ITEM 10 EXECUTIVE COMPENSATION.............................................11
   ITEM 11 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.....11
   ITEM 12 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.....................11
   ITEM 13 EXHIBITS AND REPORTS ON FORM 8-K...................................12



                                     -iii-
<PAGE>


                                     PART I

Item 1   Description of Business.

BEPARIKO BIOCOM ("Bepariko or the "Company") is a Nevada corporation formed on
April 2, 1997. The Company's offices are located at 150 West 46th Street, 5th
Floor, New York, New York 10034; (917) 450-8997. The Company operates on the
calendar fiscal year. Currently, the Company has only one employee, its sole
director and officer, and he will be the only employee for the foreseeable
future.

The details of a German patent and its inventor were brought to the attention of
Mr. Lewis Eslick, the founder and a former director and officer of the Company,
by Dipl.-Kfm. Peter Riedel, an accountant and business advisor residing in
Germany. Mr. Riedel was one of the backers that financially supported the work
necessary to obtain the patent. Following negotiations with the patent owner, it
was agreed that Mr. Eslick or his nominated company would be granted an
exclusive licensing agreement for the use of the patent.

The patent was initially registered with the Federal Republic of German under
patent number 43 22 445, and the patent was granted on June 7, 1993. The patent
was registered filed for and granted throughout the nations of the European
Economic Community. The registration of the patent in the United States and most
industrialized nations of the world followed.

Ms. Eslick elected to file Bepariko BioCom, a Nevada corporation, so that it
could be granted the exclusive licensing agreement. A set dollar amount was not
determined regarding the value of the licensing agreement.

Mr. Alfons Behnke, the patent owner, sent Mr. Tino Di Pana to the United States
with fully power of attorney to grant the exclusive licensing agreement to
Bepariko BioCom, Nevada. On April 11, 1997 our Company was granted, in
perpetuity, the unrestricted exclusive right to use of all of the rights and
privileges granted within patent 43 22 445 given by the Federal Republic of
Germany. It was verbally agreed that a percentage of any net profits earned by
our Company, through the use of the patent, would be paid to the patent owner.
This percentage would be determined on a contract by contract basis and would
not exceed 10% as a maximum cost to Bepariko.

The Company was organized to be an international corporation; a business to be
owned by the public at large and operated in accordance with the directives of
the board of directors. Bepariko's management is committed to continually
maintain, develop, and enhance its security systems to meet the changing
processing needs of the industry. In developing its service products, Bepariko
will be stressing responsiveness to the needs of its clients through client
contact and customer service.

Bepariko's multi-fingerprint access coded systems provide absolute security in
many applications. Bepariko provides an economically high quality business
solution to lowering costs, preventing fraudulent uses and providing absolute
security to its cardholders. Building new database systems is not required for
these applications. Cooperation, level-headedness and


<PAGE>


the conviction that Bepariko's multi-fingerprint access codes will lower and
then contain losses in the fields of theft and fraud for its cardholders.

Item 2   Description of Property.

The Company does not own or lease any real or personal property. The Company
currently maintains an administrative office without charge out of space donated
by the Company's President and sole director, at 150 West 46th Street, 5th
Floor, New York, New York 10034.

The Company has no policy with respect to:

1.       investments in real estate or interest in real estate;

2.       investments in real estate mortgages; or

3.       securities of or interests in persons primarily engaged in real estate
         activities.

Item 3   Legal Proceedings.

Bepariko is not a party to any material pending legal proceedings and, to the
best of its knowledge, no such action by or against the Company has been
threatened.

Item 4   Submission of Matters to a Vote of Security Holders.

No matters were submitted to a vote of the security holders during fiscal
quarter ended December 31, 2000.


                                    PART II

Item 5   Market for Common Equity and Related Stockholder Matters.

                               Market Information

Our Common Stock is currently quoted on the National Association of Securities
Dealers OTC Bulletin Board (the "OTC Bulletin Board") under the symbol "BPKO".
The Common Stock has been posted for trading on the OTC Bulletin Board since May
24, 2000, however the Common Stock has only traded since January 24, 2001. Stock
and Company information may also be obtained via the Internet. Stock market
trading values since January 24, 2001 have been as follows

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------

Period Ended:                              High                         Low                         Close
----------------------------------------------------------------------------------------------------------------------

<S>                                   <C>                          <C>                          <C>
January  24,  2001 to                     $3.50                        $1.125                       $3.50
January 31, 2001
----------------------------------------------------------------------------------------------------------------------

February 28, 2001                         $5.50                        $3.20                        $3.69
----------------------------------------------------------------------------------------------------------------------

March 1 2001 to March 23, 2001            $5.22                        $3.69                        $5.13
----------------------------------------------------------------------------------------------------------------------
</TABLE>


                                       -2-
<PAGE>


As at the close of business on March 23, 2001, the closing price of the
Company's shares on the OTC Bulletin Board was $5.13. Other than as described
above, the Company's Common Stock is not and has not been listed or quoted on
any other exchange or quotation system.

                                  Shareholders

The Company's authorized capital stock consists of 100,000,000 shares of Common
Stock, par value $.001 per share, and 10,000,000 shares of preferred stock, par
value $.0001 per share ("Preferred Stock"). As of December 31, 2000, the Company
had approximately 56 shareholders of record. A number of these shares are held
in "street" name and may, therefore, be held by several beneficial owners. As of
March 15, 2001 there are 73 holders of Company's common stock. A number of these
shares are held in "street" name and may, therefore, be held by several
beneficial owners.

                                    Dividends

Bepariko has not paid any dividends on its Common Stock. Our Company currently
intends to retain any earnings for use in its business, and does not anticipate
paying cash dividends in the foreseeable future.

Item 6   Management's Discussion and Analysis or Plan of Operation.

NOTE REGARDING PROJECTIONS AND FORWARD LOOKING STATEMENTS

This statement includes projections of future results and "forward-looking
statements" as that term is defined in Section 27A of the Securities Act of 1933
as amended (the "Securities Act"), and Section 21E of the Securities Exchange
Act of 1934 as amended (the "Exchange Act"). All statements that are included in
this filing, other than statements of historical fact, are forward-looking
statements. Although Management believes that the expectations reflected in
these forward-looking statements are reasonable, it can give no assurance that
such expectations will prove to have been correct. Important factors that could
cause actual results to differ materially from the expectations are disclosed in
this Statement, including, without limitation, in conjunction with those
forward-looking statements contained in this Statement.

                                Plan of Operation

Bepariko BioCom is working to have a minimum of 6 major contracts with
internationally recognized customers as soon as possible. Initial contacts have
been made with:

1. Unisys Corporation

2. Biometric Tracking

3. Siemens AG (Germany)

4. RJM Rheinmetal Jena, (Germany)

5. Lufthansa (Germany)

6. El Al Airlines



                                      -3-
<PAGE>


7. Bode Panzer Safes (Europe).

Bepariko will continue discussions with these and other interested companies to
complete a contract or contracts. Our company may be offered an opportunity to
joint venture with one or more of these companies to assist in furthering our
business plans. The possibility of contracts or joint ventures vary from alien
identification ID cards, entrance to airline secured areas, corporate security
and military applications.

We will continue negotiations with major industrial companies that have
expressed a desire to incorporate the use of our patent into their operational
systems. For the right to use the patent a facilitation charge will be paid to
our company. Each time a system is accessed we will receive a use fee.

We have attended security trade shows such as Secure-Tech and Card-Tech to
introduce our product to a wide sector of the market. We will continue to
display and demonstrate our product to potential markets available at these
trade shows.

Many industrial and multi-national companies that would be interested in
applying our multi-fingerprint identification system to their existing systems
prefer to operate those systems in house. This could present an opportunity for
Bepariko to enter into a joint venture with one or more of these companies. At
this time, Bepariko has no proposal, agreement, understanding or arrangement to
enter into such a joint venture agreement with any specific business or company.

Our Company will not restrict its search for business opportunities to any
specific business, industry or geographical location. The discussion of the
proposed business under this caption and throughout this Registration Statement
is purposefully general and is not meant to be restrictive of the Company's
virtually unlimited discretion to search for and enter into potential business
opportunities.

Bepariko's potential success is heavily dependent on it's management, which will
have virtually unlimited discretion in searching for and entering into business
opportunities. The sole director and officer of our company has not had any
experience in the proposed business of the Company.

Bepariko may seek to develop a new product or service, or acquire an established
business which may be experiencing financial or operating difficulties and is in
the need for additional capital which is perceived to be easier to raise by a
public company. In some instances, a business opportunity may involve the joint
venture with a corporation that does not need substantial additional cash. Our
company may purchase assets and establish wholly owned subsidiaries in various
business or purchase an existing businesses as subsidiaries.

Bepariko anticipates that the selection of a business opportunity will be
complex and extremely risky. Potentially, available business opportunities may
occur in many different industries and at various stages of development. This
will make the task of comparative investigation and analysis of any
opportunities extremely difficult and complex.

As is customary in the industry, Bepariko may pay a finder's fee for locating
and executing a contract with a company to use the multi-fingerprint patent. If
any fee is paid, it will be approved by our Company's board of directors and
will be in accordance with the industry standards. Such fees are customarily
between 1% and 5% of the size of the transaction based



                                      -4-
<PAGE>


upon a sliding scale of the amount involved. These fees are typically in the
range of 5% on a $1,000,000 transaction ratably down to 1% in a $4,000,000
transaction. Management has adopted a policy that a finder's fee could, in
certain circumstances, be paid to any employee, officer, director or 5%
shareholder of Bepariko, if this person plays a material role in bringing a
transaction to completion.

Bepariko has not formulated any policy regarding the use of consultants or
outside advisors. In the future if our Company finds it necessary to employ
consultants or outside advisors the board of directors will establish a policy
in line with policies being utilized in the industry.

Presentation of opportunities to Bepariko BioCom.

Bepariko anticipates that business opportunities for possible contracts or joint
ventures will be referred by various sources, including its officers and
directors, professional advisers, securities broker-dealers, venture
capitalists, members of the financial community, and others who may present
unsolicited proposals.

Our Company will seek a potential business opportunity from all known sources,
but will rely principally on personal contacts of its officers and directors as
well as indirect associations between them and other business and professional
people.

Bepariko's evaluation of future business.

The sole officer and director of Bepariko is currently employed in another
position. Currently Mr. Stern devotes approximately three hours each week to the
operations of the business. The sole officer and director will dedicate whatever
time is required for the operations and development of the Company's business.
Mr. Stern has other interests that require portions of his time. He currently
does not have any investments or ownership in other companies that could pose a
conflict with Bepariko.

The analysis of new business opportunities will be undertaken by or under the
supervision of the sole officer and director of Bepariko. Management intends to
concentrate on identifying prospective business opportunities that may be
brought to its attention through present associations with management. In
analyzing prospective business opportunities, management will consider the
available technical, financial and managerial resources. Working capital and
other financial requirements will be required.

Our Company must consider the quality and experience of management potentials
for further research and development. Officers and directors of each company
will meet personally with management and key personnel of the firm sponsoring
the business opportunity as part of their investigation. To the extent possible,
Bepariko intends to utilize written reports and personal investigation to
evaluate business opportunities.

Bepariko will not restrict its search for any specific kind of business, but may
contract with a company which is in its preliminary or development stage, which
is already in operation, or in essentially any stage of its corporate life.

Bepariko may enter into other business ventures.

In implementing a structure for a particular business opportunity, Bepariko may
become a party to a joint venture, franchise or licensing agreement with another
corporation or entity. It may



                                      -5-
<PAGE>


also purchase stock or assets of an existing business. On the consummation of a
transaction, it is possible that the present management and shareholders of
Bepariko will not be in control of the Company. In addition, the sole officer
and director of Bepariko may, as part of the terms of the transaction, resign
and be replaced by new officers and directors without a vote of Bepariko's
shareholders.

As part of our Company's investigation, the sole officer and director of
Bepariko will meet personally with management and key personnel. He may visit
and inspect material facilities, obtain independent analysis or verification of
certain information provided, check reference of management and key personnel,
and take any other reasonable investigative measures, to the extent of our
Company's limited financial resources and management expertise.

The manner in which our Company participates in an opportunity will depend on
the nature of the opportunity, the respective needs and desires of Bepariko and
other parties, the management of the opportunity, and the relative negotiating
strength of our Company and the other management.

Bepariko will not have sufficient funds to undertake any significant
development, marketing and manufacturing of any products which may be acquired.
Our Company will, in all likelihood, be required to either seek debt or equity
financing or obtain funding from third parties, Our Company would probably be
required to give up a substantial portion of its interest in any acquired
product. There is no assurance that our Company will be able either to obtain
additional financing or interest third parties in providing funding for the
further developing, marketing and manufacturing of any products acquired.

It is anticipated that the investigation of specific business opportunities and
the negotiation, drafting and execution of relevant agreements, disclosure
documents and other instruments will require substantial management time and
attention and substantial costs for accountants, attorneys and others. If a
decision were made not to participate in a specific business opportunity the
costs incurred in the related investigation would not be recoverable. Even if an
agreement is reached for the participation in a specific business opportunity,
the failure to consummate that transaction may result in the loss to our Company
of the related costs incurred.

Management believes that the Company may be able to benefit from the use of
"leverage" in a business opportunity. Leveraging a transaction involves the
purchase of a business through incurring significant indebtedness for a large
percentage of the purchase price for that business. Through a leveraged
transaction, the Company would be required to use less of its available funds
for purchasing the business opportunity and, therefore, could commit those funds
to the operations of the business opportunity or to other activities. The assets
of the business opportunity will ordinarily secure the borrowing involved in a
leveraged transaction.

Competition Bepariko BioCom may encounter.

Bepariko is an insignificant participant among firms, which engage in business
combinations with financing of development stage enterprises. There are many
established management and financial consulting companies and venture capital
firms which have significantly greater financial and personnel resources,
technical expertise and experience than Bepariko. In view of our Company's
limited financial resources and management availability, it will continue to be
at a significant competitive disadvantage.


                                      -6-
<PAGE>


Regulation and Taxation that may be applied to Bepariko BioCom.

The Investment Company Act of 1940 defines an "investment company" as an issuer,
which is or holds itself out as being engaged primarily in the business of
investing, reinvesting or trading of securities. While Bepariko does not intend
to engage in these activities, it could become subject to regulation under the
Investment Company Act of 1940 in the event Bepariko obtains or continues to
hold a minority interest in a number of development stage enterprises. Bepariko
could be expected to incur significant registration and compliance costs if
required to register under the Investment Company Act of 1940. Management will
continue to review the Company's activities from time to time with a view toward
reducing the likelihood that Bepariko could be classified as an "investment
company."

Events subsequent to December 31, 2000.

On March 15, 2001, Bepariko announced that it had entered into a definitive
agreement with the shareholders of Global Genomics Capital, Inc. ("GGC"), a
California company, to acquire all of the issued and outstanding shares of GGC
in exchange for the issuance by the Company of approximately 9.1 million shares
in its capital.

GGC's business strategy is to invest in and assist the development of genomics
companies that will develop and supply the hardware, software and databases
necessary for the genomics based drug development process rather than investing
in companies that are focused on developing genomics based drugs. In this way,
GGC hopes to secure interests in companies that are positioned to be technical
leaders in their respective areas of development and are capable of near term
revenue.

The acquisition of GGC is subject to a number of conditions precedent including:
the completion by the Company, of a financing of up to $10,000,000 and the
execution of the formal purchase agreement between the Company and the
shareholders of GGC.

Assuming the completion of the acquisition of GGC, the board of directors of the
Company will changed so that the sole director holding office prior to the
closing of the acquisition of GGC will appoint replacement directors nominated
by the executive stockholders of GGC, and will then resign.

Item 7   Financial Statements.

The financial statements and supplemental data required by this Item 7 follow
the index of financial statements appearing at Item 13 of this Form 10K-SB.

Item 8   Changes In and Disagreements With Accountants on Accounting and
Financial Disclosure.

Since the inception of Bepariko BioCom on April 2, 1997, the principal
independent accountant for the Company was Barry L. Friedman. Mr. Friedman
passed away on January 27, 2001, prior to commencing the audit for the fiscal
period ended December 31, 2000. The director of the Company at the time,
appointed Kurt D. Saliger, C.P.A. as the independent accountant of the Company.
Since the inception of the Company, the principal independent accountant for the
Company has neither resigned nor been dismissed, and there have been no
disagreements between the Company and the principal independent accountant for
the Company.


                                      -7-
<PAGE>


                                    PART III

Item 9   Directors, Executive Officers, Promoters and Control Persons;
Compliance With Section 16(a) of the Exchange Act.

DIRECTORS AND EXECUTIVE OFFICERS.

The members of the board of directors of Bepariko serve until the next annual
meeting of stockholders, or until their successors have been elected. The
officers serve at the pleasure of the board of directors. Shai Stern, is the
sole director and President of the Company. Mr. Stern, age 26, is the Executive
Director of Yazam.com, a company which funds seed stage start-ups with its own
capital in conjunction with a network of private investors, venture capitalists
and strategic partners. He was previously a vice-president of American Stock
Transfer & Trust Co., and then at AST Stock Plan Inc., an affiliated company
that provided administrative services for employee stock option plans.

Item 10  Executive Compensation.

No compensation is paid or anticipated by Bepariko until a contract is executed.

Directors currently receive no compensation for their duties as directors.

Item 11  Security Ownership of Certain Beneficial Owners and Management.

As at the date of this report, there are no persons who hold directly or
beneficially more than 5% of our Company's capital stock. The sole director and
officer of the Company does not currently hold beneficially or directly, any
shares of the Company's Common Stock.

Item 12  Certain Relationships and Related Transactions.

There have been no related transactions during the last two years, to which the
Company was or is to be a party, in which the sole director and officer had or
is to have a direct or indirect material interest.

As disclosed above, assuming the completion of the acquisition of GGC, the board
of directors of the Company will changed so that the sole director holding
office prior to the closing of the acquisition of GGC will appoint replacement
directors nominated by the executive stockholders of GGC, and will then resign.
The proposed replacement directors and their affiliates as a group would then
hold approximately 6.6 million shares in the capital of the Company. The changes
to the board of directors of the Company and the issuances of shares of Common
Stock to the proposed nominees are subject to the closing of the acquisition of
GGC, and may not occur.


                                      -8-
<PAGE>


Item 13  Exhibits and Reports on Form 8-K.

(a) EXHIBITS

Exhibit No.                Description

3.1                        Articles of Incorporation*

3.2                        By-Laws of Bepariko Biocom*

10.1                       Power of Attorney of Tino Di Pana*

10.2                       Exclusive Worldwide Licensing Agreement for the Right
                           to use German Patent Number 43 22 445 *

27                         Financial Data Schedule (for SEC use only)

* Filed previously

FINANCIAL STATEMENTS

                  Report of Independent Auditor, Kurt D. Saliger, C.P.A., dated
                  February 12, 2001

                  Balance sheet as of December 31, 2000, and December 31, 1999

                  Statement of Operation for the years ended December 31, 2000,
                  December 31, 1999; and for the period April 2, 1997
                  (inception) to December 31, 2000

                  Statement of Changes in Stockholders' Equity

                  Statement of Cash Flows for the years ended December 31, 2000,
                  December 31, 1999; and for the period April 2, 1997
                  (inception) to December 31, 2000

                  Notes to Financial Statements

(b) REPORTS ON FORM 8-K

There were no current reports on Form 8-K filed during the quarter ended
December 31, 2000.



                                      -9-
<PAGE>



                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                 BEPARIKO BIOCOM
-------------------------------------------
(Registrant)

By: /s/ Shai Stern
    ---------------------------------------
        Shai Stern
         President and Director*

Date:     April 2, 2001

In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the
dates indicated.

By: /s/ Shai Stern
    ---------------------------------------
        Shai Stern
         President and Director (Principal executive, financial and accounting
           officer)

Date:     April 2, 2001



                                      -10-

<PAGE>

                    [LETTERHEAD OF KURT D. SALINGER, C.P.A.]


                          INDEPENDENT AUDITOR'S REPORT

Board of Directors
Bepariko Biocom
Las Vegas, Nevada

         I have audited the accompanying balance sheets of Bepariko Biocom (a
development stage company), as of December 31, 2000 and December 31, 1999 and
the related statements of stockholders' equity for December 31, 2000 and
December 31, 1999 and statements of operations and cash flows for the two years
ended December 31, 2000 and December 31, 1999 and the period of April 2, 1997
(inception) to December 31, 2000. These financial statements are the
responsibility of the Company's management. My responsibility is to express an
opinion on these financial statements based on my audit.

         I conducted my audit in accordance with generally accepted auditing
standards. Those standards require that I plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
I believe that my audit provides a reasonable basis for my opinion.

         In my opinion, the financial statements referred to above present
fairly, in all material respects, the financial position of Bepariko Biocom as
of December 31, 2000 and December 31, 1999 and the related statements of
stockholders' equity for December 31, 2000 and December 31, 1999 and statements
of operations and cash flows for the two years ended December 31, 2000 and
December 31, 1999 and the period April 2, 1997 (inception) to December 31, 2000
in conformity with generally accepted accounting principles.

         The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. As discussed in Note 5 to the
financial statements, the Company has had no operations and has no established
source of revenue. This raises substantial doubt about its ability to continue
as a going concern. Management's plan in regard to these matters are also
described in Note 5. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.


/s/ Kurt D. Salinger C.P.A.
Kurt D. Salinger C.P.A.
February 12, 2001


<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                     ASSETS

                                                                 December 31,  December 31,
                                                                    2000          1999
<S>                                                              <C>           <C>
CURRENT ASSETS
         Cash                                                     $      0      $      0
                                                                  --------      --------
         TOTAL CURRENT ASSETS                                     $      0      $      0
                                                                  --------      --------
                  TOTAL ASSETS                                    $      0      $      0
                                                                  ========      ========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
         Officer Advances                                         $  3,100      $  1,500
                                                                  --------      --------
         TOTAL CURRENT LIABILITES                                 $  3,100      $  1,500

STOCKHOLDERS' EQUITY
         Preferred Stock, $.001 par value authorized
         10,000,000 shares; issued and outstanding at
         Dec. 31, 2000      none                                  $      0

         Common Stock, $.001 par value authorized 100,000,000
         shares; issued and outstanding at
         Dec. 31, 1999      750,000 shares                                      $    750
         Dec. 31, 2000      5,750,000 shares                      $  5,750

         Additional Paid In Capital                               $ 32,324      $ 17,324

         Deficit Accumulated During Development Stage             ($41,174)     ($19,574)
                                                                  --------      --------
         TOTAL STOCKHOLDERS' EQUITY                               ($ 3,100)     ($ 1,500)
                                                                  --------      --------
                  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY      $      0      $      0
                                                                  ========      ========
</TABLE>

         See accompanying notes to financial statements.

                                      -2-
<PAGE>



                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                             STATEMENT OF OPERATIONS

                                                                  April 2, 1997
                                Year Ended       Year Ended       (inception) to
                                Dec. 31, 2000    Dec. 31, 1999    Dec. 31, 2000

INCOME
Revenue                         $         0      $         0      $         0
                                -----------      -----------      -----------
TOTAL INCOME                    $         0      $         0      $         0

EXPENSES

General, Selling
and Administrative              $    21,600      $     1,500      $    41,024

Amortization                    $         0      $        98      $       150




                                -----------      -----------      -----------
TOTAL EXPENSES                  $    21,600      $     1,598      $    41,174
                                -----------      -----------      -----------
NET PROFIT (LOSS)               ($   21,600)     ($    1,598)     ($   41,174)
                                ===========      ===========      ===========

NET PROFIT (LOSS)
PER SHARE                       ($   0.0038)     ($   0.0021)     ($   0.0072)
                                ===========      ===========      ===========


AVERAGE NUMBER OF SHARES
OF COMMON STOCK OUTSTANDING       5,750,000          750,000        5,750,000
                                ===========      ===========      ===========


                 See accompanying notes to financial statements.

                                      -3-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                  STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
                                December 31, 2000

<TABLE>
<CAPTION>
                                                            Common Stock                            (Deficit)
                                                           --------------                          Accumulated
                                                        Number                      Additional       During
                                                          of                         Paid In       Development
                                                        Shares         Amount        Capital         Stage
                                                      ----------     ----------     ----------     ----------

<S>                                                   <C>            <C>            <C>            <C>
Balance,
December 31, 1998                                        750,000     $      750     $   17,324     ($  17,976)

Net Loss,
December 31, 1999                                                                                  ($   1,598)
                                                      ----------     ----------     ----------     ----------
Balance, Dec. 31, 1999                                   750,000     $      750     $   17,324     ($  19,574)

Issued for cash
January 21, 2000                                       5,000,000     $    5,000     $   15,000     $        0

Net Loss,
December 31, 2000                                                                                  ($  21,600)
                                                      ----------     ----------     ----------     ----------

Balance,
December 31, 2000                                      5,750,000     $    5,750     $   32,234     ($  41,174)
                                                      ==========     ==========     ==========     ==========
</TABLE>

         See accompanying notes to financial statements.

                                      -4-
<PAGE>



                                 BEPARIKO BIOCOM

                          (A Development Stage Company)

                             STATEMENT OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                       Year           Year        April 2, 1997
                                                                       Ended          Ended        (inception)
                                                                      December       December         to Dec
                                                                      31, 2000       31, 1999        31, 2000

<S>                                                                  <C>            <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES

Net (Loss)                                                           ($  21,600)    ($   1,598)    ($  41,174)

Adjustment to reconcile net loss to net cash provided
by operating activities

Amortization                                                         $        0     $       98     $      150
Officer Advances                                                     $    1,600     $    1,500     $    3,100
Organization Costs                                                                                ($      150)
                                                                     ----------     ----------     ----------

Net cash used in operating activities                               ($   20,000)    $        0    ($   38,074)

CASH FLOWS FROM
FINANCING ACTIVITIES
Issue Common Stock                                                   $   20,000     $        0     $   38,074
                                                                     ----------     ----------     ----------

Net increase (decrease) in cash                                      $        0     $        0     $        0

Cash, Beginning of Period                                            $        0     $        0     $        0
                                                                     ----------     ----------     ----------
Cash, End of Period                                                  $        0     $        0     $        0
                                                                     ==========     ==========     ==========
</TABLE>

                 See accompanying notes to financial statements.

                                      -5-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2000 and December 31, 1999

NOTE 1 - ORGANIZATION AND ACCOUNTING POLICIES

         The Company was incorporated April 2, 1997 under the laws of the State
of Nevada. The Company was organized to engage in any lawful activity. The
Company currently has no operations and, in accordance with SFAS #7, is
considered a development stage company.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     Accounting Method
         The Company records income and expenses on the accrual method of
         accounting.

     Estimates
         The preparation of financial statements in conformity with generally
         accepted accounting principles requires management to make estimates
         and assumptions that affect the reported amounts of assets and
         liabilities and disclosure of contingent assets and liabilities at the
         date of the financial statements and the reported amounts of revenue
         and expenses during the reporting period. Actual results could differ
         from those estimates.

     Cash and equivalents
         The Company maintains a cash balance in a non-interest bearing bank
         that currently does not exceed federally insured limits. For the
         purpose of the statements of cash flows, all highly liquid investments
         with the maturity of three months or less are considered to be cash
         equivalents. There are no cash equivalents as of December 31, 2000.

     Income Taxes
         Income taxes are provided for using the liability method of accounting
         in accordance with Statement of Financial Accounting Standards No. 109
         (SFAS #109) "Accounting for Income Taxes". A deferred tax asset or
         liability is recorded for all temporary differences between financial
         and tax reporting. Deferred tax expense (benefit) results from the net
         change during the year of deferred tax assets and liabilities.


                                      -6-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2000 and December 31, 1999

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

     Reporting on Costs of Start-Up Activities
         In April 1998, the American Institute of Certified Public Accountants
         issued Statement of position 98-5 ("SOP 98-5"), "Reporting the Costs of
         Start-up Activities" which provides guidance on the financial reporting
         of start-up costs and organizational costs. It requires costs of
         start-up activities and organizational costs to be expensed as
         incurred. SOP 98-5 is effective for fiscal years beginning after
         December 15, 1998 with initial adoption reported as the cumulative
         effect of a change in accounting principle.

     Loss Per Share
         Net loss per share is provided in accordance with Statement of
         Financial Accounting Standards No. 128 (SFAS #128) "Earnings Per
         Share". Basic loss per share is computed by dividing losses available
         to common stockholders by the weighted average number of common shares
         outstanding during the period. Diluted loss per share reflects per
         share amounts that would have resulted if dilutive common stock
         equivalents had been converted to common stock. As of December 31, 2000
         the Company had no dilutive common stock equivalents such as stock
         options.

     Year End
         The Company has selected December 31st as its fiscal year end.

     Year 2000 Disclosure
         The year 2000 issue had no effect on the Company.

NOTE 3 - INCOME TAXES

         There is no provision for income taxes for the year ended December 31,
         2000. The Company's total deferred tax asset as of December 31, 2000 is
         as follows:
                  Net operating loss carry forward                       $41,174
                  Valuation allowance                                    $41,174
                  Net deferred tax asset                                 $     0
         The federal net operating loss carry forward will expire in 2017 to
         2019.

                                      -7-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2000 and December 31, 1999

NOTE 4 - STOCKHOLDERS' EQUITY

     Common Stock
         The authorized common stock of the Company consists of 100,000,000
         shares with a par value of $0.001 per share.

         On July 24, 1997 the Company issued 750,000 shares of its $0.001 par
         value common stock in consideration of $18,074 in cash to its
         directors.

         On January 21, 2000 the Company completed a public offering that was
         registered with the State of Nevada pursuant to N.R.S. 90.490 and was
         in compliance with federal registration pursuant to the Form SB-2 filed
         with the Securities and Exchange Commission being declared effective on
         December 22, 1999. Subsequently, the Company sold 5,000,000 shares of
         its common stock at a share price of $0.004 per share for a total of
         $20,000 cash.

     Preferred Stock

         The authorized preferred stock of the Company consists of 10,000,000
         shares with a par value of $0.001 per share.

NOTE 5 - GOING CONCERN

         The Company's financial statements are prepared using general accepted
         accounting principles applicable to a going concern which contemplates
         the realization of assets and liquidation of liabilities in the normal
         course of business. However, the Company does not have significant cash
         or other material assets, nor does it have an established source of
         revenues sufficient to cover its operating costs and to allow it to
         continue as a going concern.


                                      -8-
<PAGE>


                                 BEPARIKO BIOCOM
                          (A Development Stage Company)
                          NOTES TO FINANCIAL STATEMENTS
                     December 31, 2000 and December 31, 1999

NOTE 6 - RELATED PARTY TRANSACTIONS

     The Company neither owns nor leases any real or personal property. An
     officer of the Company provides office services without charge. Such costs
     are immaterial to the financial statements and accordingly, have not been
     reflected therein. The officers and directors of the Company are involved
     in other business opportunities. If a specific business opportunity becomes
     available, such persons may face a conflict in selecting between the
     Company and their other business interests. The Company has not formulated
     a policy for the resolution of such conflicts.

NOTE 7 - WARRANTS AND OPTIONS

     There are no warrants or options outstanding to acquire any additional
     shares of common or preferred stock.

NOTE 8 - OFFICER ADVANCES

     While the Company was seeking additional capital to advance its business
     plan, an officer of the Company has advanced funds on behalf of the Company
     to pay for any costs incurred by it. These funds are interest free.

                                      -9-